scholarly journals Real‐world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype

2020 ◽  
Vol 27 (10) ◽  
pp. 996-1002
Author(s):  
Kevin G. Pollock ◽  
Scott A. McDonald ◽  
Rory Gunson ◽  
Allan McLeod ◽  
April Went ◽  
...  
Keyword(s):  
Viral Load ◽  
Real World ◽  
Core Antigen ◽  
Hcv Rna ◽  
Hcv Core Antigen

Clinical Usefulness of HCV Core Antigen Assay for the Management of Patients with Chronic Hepatitis C

2014 ◽  
Vol 23 (4) ◽  
pp. 393-396 ◽  
Author(s):  
Dragos Florea ◽  
Emil Neaga ◽  
Ionelia Nicolae ◽  
Daniela Maxim ◽  
Madalina Popa ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Tertiary Care ◽  
High Specificity ◽  
Core Antigen ◽  
Hcv Rna ◽  
Test Accuracy ◽  
Molecular Tests ◽  
Hcv Core Antigen ◽  
Using Data

Aim: The study aimed to evaluate the clinical utility of the chemiluminescent HCV core Ag test compared to viral load assessment in the management of patients with chronic hepatitis C.Methods: A retrospective study was performed at a tertiary-care infectious diseases hospital on samples collected from anti-HCV positive patients. Seventy-six samples were tested with the Architect HCV core Antigen kit and Cobas AmpliPrep/Cobas Taqman HCV kit. The HCV Ag test accuracy was estimated using data from all the HCV RNA tested samples received between January 2011 and December 2012.Results: The HCV Ag test showed a good correlation between the logarithmic values of HCV RNA and HCV Ag (R=0.98), with a 100% specificity and PPV, but with reduced sensitivity for viral loads lower than 1,000 UI/ mL. In a model using data from 2,478 HCV RNA tested samples and a cut-off of the Ag assay corresponding to 1,000 UI/mL HCV RNA, the Ag test would have a sensitivity of 82.4%, a NPV of 80.9% and a high specificity and PPV (100%) compared to the viral load. The sensitivity would be higher for baseline evaluation compared to on-treatment samples (98.5 vs. 50%). The highest NPV (98%) would be obtained at 48 and 72 weeks after the initiation of treatment, with a sensitivity of 88.2% and 96.1%, respectively.Conclusion: The Architect HCV core Ag assay might be an alternative for the diagnosis of active HCV infection if molecular tests are not available, and a useful method for the evaluation of sustained virological response in treated patients.

scholarly journals HCV Core Antigen as an alternative test to Quantitative HCV RNA for assessment of SVR in Chronic HCV infected patients treated with Direct Acting Antiviral agents

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
S M Mohamed ◽  
N I Musa ◽  
R S Ghait ◽  
B M Abdelrhiem
Keyword(s):  
Antiviral Agents ◽  
Virologic Response ◽  
Hcv Infection ◽  
Core Antigen ◽  
Hcv Rna ◽  
Viral Kinetics ◽  
Direct Acting Antiviral ◽  
Hcv Core Antigen ◽  
End Of Treatment ◽  
Direct Acting

Abstract Background and aims Widespread use of direct-acting antiviral (DAA) agents to treat patients with hepatitis C virus (HCV) infection has reduced the need for monitoring of HCV-RNA levels, because viral kinetics do not predict sustained virologic response (SVR) to these drugs. However, the performance of cheaper tests, such as the assay to quantify HCV core antigen (HCV Ag), has not been determined. This study was aimed at investigating the accuracy of the HCV Ag test in predicting which patients receiving DAAs will achieve SVR at week 12 (SVR12). Methods We performed a prospective study on 90 patients, chronically infected with HCV, receiving DAAs therapy from different NCCVH centers in Cairo during the period from August 2017 to June 2018. We collected blood samples and measured the levels of HCV core Ag and HCV-RNA at baseline and 12 weeks after end of treatment. We compared the ability of these assays to predict which patients would have SVR12. Results The median baseline level of HCV-RNA was 1688529.6 ± 994697.3 IU/ml (range, 312700 IU/ml to 3491100 IU/ml) and HCV Ag was 179.2 ± 83.5 pg/ml (range, 33.5 pg/ml to 315.6 pg/ml). HCV Ag became undetectable in 92.2% 12 weeks after the end of treatment. HCV-RNA became undetectable in 87.8% at the end of treatment (P<.0001). 79 out of 90 patients (87.8%) achieved an SVR12; the test for HCV Ag identified 63.6% of these patients. Conclusions Tests that measure HCV Ag monitor efficacy of DAA therapy for HCV infection as well as assays that measure HCV-RNA, and hence could be recommended for clinical practice.

scholarly journals A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS?

2018 ◽  
Vol 1 (suppl_1) ◽  
pp. 305-306
Author(s):  
S Almarzooqi ◽  
M van Tilborg ◽  
R Maan ◽  
J Vermehren ◽  
B Maasoumy ◽  
...  
Keyword(s):  
Core Antigen ◽  
Hcv Rna ◽  
Direct Acting Antivirals ◽  
Hcv Core Antigen ◽  
Direct Acting

HCV core-antigen assay as an alternative to HCV RNA quantification: A correlation study for the assessment of HCV viremia

2018 ◽  
Vol 36 (3) ◽  
pp. 175-178
Author(s):  
Roberto Alonso ◽  
Felipe Pèc)rez-García ◽  
Paula López-Roa ◽  
Luis Alcalá ◽  
Pilar Rodeño ◽  
...  
Keyword(s):  
Correlation Study ◽  
Core Antigen ◽  
Hcv Rna ◽  
Rna Quantification ◽  
Hcv Core Antigen ◽  
Antigen Assay

scholarly journals HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients

2017 ◽  
Vol 245 ◽  
pp. 14-18 ◽  
Author(s):  
Jürgen Kurt Rockstroh ◽  
Jordan J. Feld ◽  
Stéphane Chevaliez ◽  
Kevin Cheng ◽  
Heiner Wedemeyer ◽  
...  
Keyword(s):  
Core Antigen ◽  
Hcv Rna ◽  
Genotype 1 ◽  
Hcv Genotype ◽  
Hcv Core Antigen ◽  
Free Treatment ◽  
Alternate Test ◽  
Hcv Genotype 1
Sign in / Sign up

Export Citation Format

Share Document